Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Avenue Therapeutics, Inc. (ATXI : OTC)

• Company Description    Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $0.25 Daily Weekly Monthly 20 Day Moving Average: 6,418 shares Shares Outstanding: 3.18 (millions) Market Capitalization: $0.80 (millions) Beta: -0.08 52 Week High: $3.93 52 Week Low: $0.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.14% -14.47% 12 Week -4.94% -20.04% Year To Date -87.40% -88.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1111 Kane Concourse Suite 301 - Bay Harbor Islands,FL 33154 USA ph: 781-652-4500 fax: - ir@avenuetx.com http://www.avenuetx.com

• General Corporate Information    Officers Alexandra MacLean - Chief Executive Officer and Director Jay Kranzler - Chairman of the Board David Jin - Chief Operating Officer and Chief Financial Office Faith Charles - Director Neil Herskowitz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 05360L403 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 3.18 Most Recent Split Date: 4.00 (0.01:1) Beta: -0.08 Market Capitalization: $0.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 95.97% vs. Previous Quarter: -141.89% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -14.65 12/31/24 - -123.12 ROA 06/30/25 - - 03/31/25 - -10.20 12/31/24 - -83.62 Current Ratio 06/30/25 - - 03/31/25 - 2.85 12/31/24 - 3.27 Quick Ratio 06/30/25 - - 03/31/25 - 2.85 12/31/24 - 3.27 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.74 12/31/24 - 0.88 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©